Legal status
Legal status
  • Investigational New Drug
CAS Number 924012-43-1
PubChem (CID) 16095349
ChemSpider 17253639
Chemical and physical data
Formula C15H15N
Molar mass 209.28 g/mol
3D model (Jmol) Interactive image

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) under development by Neurovance in collaboration with Euthymics Bioscience as a treatment for attention deficit hyperactivity disorder (ADHD) that inhibits the reuptake of norepinephrine, dopamine and serotonin with a ratio of 1:6:14, respectively.[1][2][3] As of August 2015, it is in phase II clinical trials.

See also


This article is issued from Wikipedia - version of the 5/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.